Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity Treatment

Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity Treatment

SYNT-101 was well tolerated across all doses with no related GI adverse events, no serious adverse events, and no discontinuations

Data confirm SYNT-101's intended mechanism of nutrient redirection, with reduced glucose absorption and favorable changes in satiety hormones after a single dose

Additional data from the multiple ascending dose arm of the trial in obese patients is expected later this year

Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced initial safety, tolerability, and pharmacodynamic data from the single ascending dose (SAD) arm of its ongoing Phase 1/1b SYNTIETY-1 clinical trial evaluating SYNT-101.